Impacts of nursery-based propagation and out-planting on coral-associated bacterial communities

Coral Reefs - Efforts to manage coral reef declines are increasingly turning towards in situ propagation of corals to aid reef recovery. Understanding the factors that influence...     

Relationship between cell-mediated and humoral immune attack on tumor cells: II. The role of cellular lipid metabolism and cell surface charge in the outcome of immune attack

Treatment of P815 tumor cells with adriamycin increased their sensitivity to killing by anti-P815 antibody plus C, but not by allogeneic P815-sensitized spleen cells. Conversely, mitomycin C treatment enhanced the cells' sensitivity to cell-mediated, but not antibody-C, killing. Hydrocortisone, but not epinephrine, was effective in increasing the resistance of the cells to killing by both antibody-C and cell-mediated attack systems. The ability of the tumor cells to resist antibody-C killing correlated with their ability to incorporate fatty acid into complex cellular lipid; no such correlation was found between the cellular lipid synthesis and tumor cell susceptibility to cell-mediated killing. Drug or hormone-treated tumor cells exhibited unique changes in cellular lipid synthesis and composition and in cell surface physical properties that correlated with their susceptibility to antibody-C or cell-mediated attack. Cells increased in their sensitivity to antibody-C killing exhibited a decreased cholesterol:phospholipid mole ratio. In contrast, cells rendered more sensitive to cell-mediated killing exhibited an increase in polar phospholipid content and a measurable decrease in net negative cell surface charge density. These data implicate unique chemical and/or physical properties of tumor cells to be of fundamental importance for their ability to resist either humoral or cell-mediated immunologic attack; modulation of one or another of these cellular properties results in a change in the cells' susceptibility to immune killing by antibody plus C or by cytotoxic T lymphocytes.